Slingshot Biosciences develops synthetic cells for a range of applications in diagnostics and therapeutics. Slingshot leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an industry-first, off-the-shelf solution for cell-like reagents that are stable, low-cost, and targeted toward a range of indications and markets
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/06/23 | $11,000,000 | Series A-3 |
Anterra Capital ARCH Venture Partners | undisclosed |
